Analysts expect Rein Therapeutics, Inc. to report revenue of 0.00 for Q3 26, against a range of 0.00 to 0.00. The most recent reported quarter, Q2 26, came in at 0.00.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | - |
| High Estimate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Low Estimate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Consensus Estimate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analysts expect Rein Therapeutics, Inc. to report earnings per share of -0.10 for Q3 26, against a range of -0.11 to -0.09. The most recent reported quarter, Q2 26, came in at -0.10, a 37.5% beat against the -0.16 consensus.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -0.27 | -1.89 | -0.25 | -0.28 | -0.21 | -1.09 | -0.19 | -0.10 | - | - | - | - | - | - | - | - | ||||||||||
| High Estimate | -0.23 | -0.30 | -0.21 | -0.20 | -0.24 | -1.03 | -0.44 | -0.15 | -0.09 | -0.13 | -0.09 | -0.11 | -0.06 | -0.26 | 0.07 | -0.08 | ||||||||||
| Low Estimate | -0.27 | -0.34 | -0.23 | -0.22 | -0.28 | -1.25 | -0.52 | -0.17 | -0.11 | -0.15 | -0.11 | -0.11 | -0.08 | -0.28 | 0.07 | -0.10 | ||||||||||
| Consensus Estimate | -0.25 | -0.32 | -0.22 | -0.21 | -0.26 | -1.14 | -0.48 | -0.16 | -0.10 | -0.14 | -0.10 | -0.11 | -0.07 | -0.27 | 0.07 | -0.09 |